

**South East London Integrated Medicines Optimisation Committee
Formulary recommendation**

Reference	150
Intervention:	Olopatadine hydrochloride and mometasone furoate monohydrate combination nasal spray (Ryaltris™) for the treatment of moderate to severe allergic rhinitis in adults and children 12 years and older (Ryaltris™ is a nasal spray containing a combination of an antihistamine [to reduce allergy symptoms] and a corticosteroid [to reduce inflammation]).
Date of Decision:	May 2024
Date of Issue:	August 2024
Recommendation	GREEN – can be prescribed within agreed criteria for use in primary or secondary care
Further Information:	<ul style="list-style-type: none"> • In line with its licenced use*, olopatadine hydrochloride and mometasone furoate monohydrate combination nasal spray (Ryaltris™) is accepted for use within South East London for the management of moderate to severe allergic rhinitis. • In line with the South East London Acute Provider Collaborative's (SEL APC) Ear, Nose and Throat (ENT) interface guidelines, Ryaltris™ can be considered as a last line option at the same point in therapy as Dymista™ in primary care, before referral to specialist allergy services is considered. Note: There are two separate APC guidelines for ENT conditions – one for adults and one for children. • Formulary recommendation 067 details the use of Dymista™ within SEL. • Please refer to the allergic rhinitis section within the SEL APC ENT interface guidelines for information on the treatment steps that should be trialled before Ryaltris™ is considered. Treatment options are based on the severity of the allergic rhinitis and specific treatment options are noted within the guidelines. • Prescribers should educate patients on proper application technique, potential side effects and precautions of use of Ryaltris™. Additionally, a clear treatment plan should be established for ongoing use in the community <p>Practical issues (refer also to summary of product characteristics (SPC) and patient information leaflet for more detailed information):</p> <ul style="list-style-type: none"> • The dose for adults and children aged 12 years and over is two actuations of the spray in each nostril twice daily (morning and evening). • One actuation of the spray delivers 25 micrograms mometasone furoate and 600 micrograms olopatadine. • Ryaltris™ is not recommended for use in children below 12 years of age as safety and efficacy has not been established in this age group. Use in this age group would be unlicensed and is not covered by this recommendation and the SEL APC ENT interface guidelines for children and young people. • The duration of treatment should correspond to the period of allergenic exposure. • If Ryaltris™ is not used for 14 days or longer, re-prime the pump with 2 actuations until a uniform spray is observed, before next use. • Ryaltris™ can be stopped if side effects are not tolerated and/or there is a lack of efficacy or resolution of nasal symptoms despite good compliance. <p>*Ryaltris™ is licenced for adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis.</p>
Shared Care/Transfer of care document required:	N/A
Cost Impact for	<ul style="list-style-type: none"> • The annual cost of treatment with Ryaltris™ per patient is £159.84. As Ryaltris™ will

agreed patient group	be used at the same point in therapy as Dymista™, the cost impact will be a substitution and could be cost saving. There may also be an opportunity for savings from reduced referrals to specialist allergy clinics as the SEL APC ENT interface guidelines support more management in primary care.
Usage Monitoring & Impact Assessment	<p>Acute Trusts:</p> <ul style="list-style-type: none"> Monitor and audit usage of Ryaltris™ and report back to the Committee (against this recommendation) upon request of the Committee <p>SEL Borough Medicines Optimisation Teams:</p> <ul style="list-style-type: none"> Monitor primary care prescribing data. Exception reports from GPs if inappropriate prescribing requests are made to primary care.
Evidence reviewed	<p>References (from evidence evaluation):</p> <ol style="list-style-type: none"> Allergic Rhinitis. NICE CKS. Available here: [Accessed: 03 May 2024] Scadding GK, Kariyawasam HH, Scadding G, Mirakian R, Buckley RJ, Dixon T, Durham SR, Farooque S, Jones N, Leech S, Nasser SM, Powell R, Roberts G, Rotiroti G, Simpson A, Smith H, Clark AT. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy. 2017 Jul;47(7):856-889. doi: 10.1111/cea.12953. PMID: 30239057. Dymista 137 micrograms / 50 micrograms per actuation nasal spray - summary of product characteristics (SmPC) - (EMC). Available here: [Accessed: 03 May 2024] South East London Joint Medicines Formulary. Available here: [Accessed 03 May 2024] SE London Acute Provider Collaborative: ENT Adult Primary and Secondary Care Interface Guidelines. Available here: [Accessed 03 May 2024] Ryaltris 25 micrograms/actuation + 600 micrograms/actuation nasal spray, suspension - summary of product characteristics (SmPC) - (EMC). Available here: [Accessed: 03 May 2024] Olopatadine hydrochloride and Mometasone furoate monohydrate (Ryaltris). Scottish Medicines Consortium. Available here: [Accessed: 03 May 2024] Swedish Medical Products Agency, "Public Assessment Report Ryaltris SE/H/2040/01/DC/2020-0001," April 2021. [Online]. Available here: [Accessed: 03 May 2024] Gross GN, Berman G, Amar NJ, Caracta CF, Tantry SK. Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2019 Jun;122(6):630-638.e3. doi: 10.1016/j.anai.2019.03.017. Epub 2019 Mar 22. PMID: 30910440. Hampel FC, Pedinoff AJ, Jacobs RL, Caracta CF, Tantry SK. Olopatadine-mometasone combination nasal spray: Evaluation of efficacy and safety in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2019 Jul 3;40(4):261-272. doi: 10.2500/aap.2019.40.4223. Epub 2019 May 3. PMID: 31053180

NOTES:

- SEL IMOC recommendations and minutes are available publicly via the [website](#).
- This SEL IMOC recommendation has been made on the cost effectiveness, patient outcome and safety data available at the time. The recommendation will be subject to review if new data becomes available, costs are higher than expected or new NICE guidelines or technology appraisals are issued.
- Not to be used for commercial or marketing purposes. Strictly for use within the NHS.**